A pivotal Supreme Court ruling on January 30, 2026, has fundamentally reshaped India’s regenerative medicine landscape by definitively classifying stem cells as "drugs," thereby ending years of regulatory ambiguity and ushering in a new era of stringent oversight. For years, India's b
A sector once defined by predictable growth and investor confidence now finds itself navigating a landscape of escalating costs and unsettling regulatory forecasts, prompting a fundamental reassessment of its financial health. The U.S. health insurance industry, a complex machine responsible for
The intricate network of modern healthcare, heavily reliant on diagnostic imaging for timely and accurate patient outcomes, is currently straining under the weight of a crisis that is both unprecedented and unsustainable. With patient demand surging and a workforce in steady decline, the radiology
The journey from a groundbreaking scientific discovery in a university laboratory to a life-saving medicine on a pharmacy shelf is one of the most challenging and capital-intensive paths in any industry. With its recent first close of over $145 million for its fourth fund, transatlantic venture
Following an extensive nine-hour congressional session with top health insurance executives, it has become undeniably clear that the American healthcare affordability crisis is a systemic issue demanding a comprehensive, system-wide resolution. The labyrinth of rising premiums, staggering
Today, we're joined by Faisal Zain, a leading expert in medical technology, to explore the dynamic and often uncertain future of clinical diagnostics. As rapid advancements in AI, at-home testing, and data connectivity reshape healthcare, we'll delve into the practical challenges and
